vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and Enovis CORP (ENOV). Click either name above to swap in a different company.
Enovis CORP is the larger business by last-quarter revenue ($548.9M vs $255, roughly 2152596.1× Bone Biologics Corp). Enovis CORP runs the higher net margin — -104.1% vs -339596.1%, a 339492.0% gap on every dollar of revenue. On growth, Enovis CORP posted the faster year-over-year revenue change (-2.2% vs -54.1%).
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.
BBLG vs ENOV — Head-to-Head
Income Statement — Q1 2024 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $255 | $548.9M |
| Net Profit | $-866.0K | $-571.1M |
| Gross Margin | — | 59.9% |
| Operating Margin | -354327.8% | -101.7% |
| Net Margin | -339596.1% | -104.1% |
| Revenue YoY | -54.1% | -2.2% |
| Net Profit YoY | 76.7% | 18.8% |
| EPS (diluted) | $-1.31 | $-9.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $548.9M | ||
| Q3 25 | — | $564.5M | ||
| Q2 25 | — | $558.8M | ||
| Q4 24 | — | $561.0M | ||
| Q3 24 | — | $505.2M | ||
| Q2 24 | — | $525.2M | ||
| Q1 24 | $255 | $516.3M | ||
| Q4 23 | $348 | $455.0M |
| Q4 25 | — | $-571.1M | ||
| Q3 25 | — | $-36.7M | ||
| Q2 25 | — | $-56.0M | ||
| Q4 24 | — | $-703.2M | ||
| Q3 24 | — | $-31.5M | ||
| Q2 24 | — | $-18.6M | ||
| Q1 24 | $-866.0K | $-72.0M | ||
| Q4 23 | $-1.5M | $3.1M |
| Q4 25 | — | 59.9% | ||
| Q3 25 | — | 59.3% | ||
| Q2 25 | — | 59.5% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 56.7% | ||
| Q2 24 | — | 55.0% | ||
| Q1 24 | — | 57.7% | ||
| Q4 23 | — | 58.1% |
| Q4 25 | — | -101.7% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | — | -8.4% | ||
| Q4 24 | — | -118.5% | ||
| Q3 24 | — | -6.3% | ||
| Q2 24 | — | -8.4% | ||
| Q1 24 | -354327.8% | -6.8% | ||
| Q4 23 | -333335.6% | -1.3% |
| Q4 25 | — | -104.1% | ||
| Q3 25 | — | -6.5% | ||
| Q2 25 | — | -10.0% | ||
| Q4 24 | — | -125.4% | ||
| Q3 24 | — | -6.2% | ||
| Q2 24 | — | -3.5% | ||
| Q1 24 | -339596.1% | -13.9% | ||
| Q4 23 | -445369.3% | 0.7% |
| Q4 25 | — | $-9.99 | ||
| Q3 25 | — | $-0.64 | ||
| Q2 25 | — | $-0.98 | ||
| Q4 24 | — | $-12.69 | ||
| Q3 24 | — | $-0.58 | ||
| Q2 24 | — | $-0.34 | ||
| Q1 24 | $-1.31 | $-1.32 | ||
| Q4 23 | $31.30 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $33.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $3.7M | $2.0B |
| Total Assets | $3.8M | $4.4B |
| Debt / EquityLower = less leverage | — | 0.67× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $33.6M | ||
| Q3 25 | — | $44.1M | ||
| Q2 25 | — | $38.5M | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | — | $35.4M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $66.3M | ||
| Q4 23 | — | $36.2M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B | ||
| Q4 23 | — | $466.2M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | $3.7M | $3.3B | ||
| Q4 23 | $2.9M | $3.4B |
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $4.9B | ||
| Q4 24 | — | $4.7B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | $3.8M | $5.5B | ||
| Q4 23 | $3.7M | $4.5B |
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.53× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.40× | ||
| Q4 23 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $82.6M |
| Free Cash FlowOCF − Capex | — | $29.1M |
| FCF MarginFCF / Revenue | — | 5.3% |
| Capex IntensityCapex / Revenue | — | 9.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $22.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $82.6M | ||
| Q3 25 | — | $47.8M | ||
| Q2 25 | — | $-1.6M | ||
| Q4 24 | — | $88.3M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | — | $7.8M | ||
| Q1 24 | $-1.3M | $-36.2M | ||
| Q4 23 | $-2.0M | $68.4M |
| Q4 25 | — | $29.1M | ||
| Q3 25 | — | $3.4M | ||
| Q2 25 | — | $-44.9M | ||
| Q4 24 | — | $35.1M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | $-31.6M | ||
| Q1 24 | — | $-73.1M | ||
| Q4 23 | — | $40.5M |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | -8.0% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | -6.0% | ||
| Q1 24 | — | -14.2% | ||
| Q4 23 | — | 8.9% |
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 7.7% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | — | 7.5% | ||
| Q1 24 | — | 7.2% | ||
| Q4 23 | — | 6.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 22.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBLG
Segment breakdown not available.
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
